Egheny Health Method, Pittsburgh, PA, USA; 8University of Calgary, AB, Canada

Izvor: Public Policy Institut Wiki
Izmena od 23:06, 7. decembar 2017.; Dibble2week (razgovor | doprinosi) (Nova stranica: Egheny Health Technique, Pittsburgh, PA, USA; 8University of Calgary, AB, Canada; 9 Lund University Hospital, Lund, Sweden; 10The Hospital for RheumaticA16 Lymphoma danger in syste…)

(razl) ← Starija izmena | Tekuća izmena (razl) | Novija izmena → (razl)
Idi na: navigaciju, pretragu

Egheny Health Technique, Pittsburgh, PA, USA; 8University of Calgary, AB, Canada; 9 Lund University Hospital, Lund, Sweden; 10The Hospital for RheumaticA16 Lymphoma danger in systemic lupus: effects of therapy versus illness activity AE Clarke1*, S Bernatsky1, KH Costenbader2, MB Urowitz3, DD Gladman3, PR Fortin4, M Petri5, S Manzi6, DA Isenberg7, A Rahman7, D Wallace8, C Gordon9, C Peschken10, MA Dooley11, EM Ginzler12, C Aranow13, SM Edworthy14, O Nived15, S Jacobsen16, G Ruiz-Irastorza17, E Yelin18, SG Barr14, L Criswell18, G Sturfelt15, L Dreyer16, I Blanco19, L Gottesman12, CH Feldman2, R Ramsey-Goldman20 1 Study Institute on the McGill University Overall health Centre, Montreal, QC, Canada; 2Brigham and Women's Hospital, Harvard Health-related School, Boston, MA, USA; 3Toronto Western Hospital and University of Toronto, Toronto, ON, Canada; 4University of Laval, QC, Canada; 5Johns Hopkins University College of Medicine, Baltimore, MD, USA; 6West Penn Allegheny Well being System,Arthritis Analysis Therapy 2012, Volume 14 Suppl 3 http://arthritis-research.com/supplements/14/SPage 7 ofPittsburgh, PA, USA; 7University College of London, UK; 8Cedars-Sinai/UCLA, Los Angeles, CA, USA; 9University of Birmingham, UK; 10University of Manitoba, Winnipeg, MB, Canada; 11University of North Carolina at Chapel Hill, NC, USA; 12SUNY - Downstate Medical Center, Brooklyn, NY, USA; 13 title= rstb.2014.0252 Feinstein Institute for Healthcare Study, Manhasset, NY, USA; 14The University of Calgary, AB, Canada; 15University Hospital - Lund, Sweden; 16 Copenhagen University Hospital, Copenhagen, Denmark; 17Hospital de Cruces, UPV/EHU, Barakaldo, Spain; 18University of California San Francisco, CA, USA; 19Albert Einstein College of Medicine, Bronx, NY, USA; 20 Northwestern University Feinberg College of Medicine, Chicago, IL, USA Arthritis Study Therapy 2012, 14(Suppl 3):ABackground: We not too long ago evaluated the danger of malignancy in SLE by linking a multi-site international SLE cohort with regional tumor Lorlatinib biological activity registries. Lympho.Egheny Wellness Technique, Pittsburgh, PA, USA; 8University of Calgary, AB, Canada; 9 Lund University Hospital, Lund, Sweden; 10The Hospital for RheumaticA16 Lymphoma threat in systemic lupus: effects of remedy versus disease activity AE Clarke1*, S Bernatsky1, KH Costenbader2, MB Urowitz3, DD Gladman3, PR Fortin4, M Petri5, S Manzi6, DA Isenberg7, A Rahman7, D Wallace8, C Gordon9, C Peschken10, MA Dooley11, EM Ginzler12, C Aranow13, SM Edworthy14, O Nived15, S Jacobsen16, G Ruiz-Irastorza17, E Yelin18, SG Barr14, L Criswell18, G Sturfelt15, L Dreyer16, I Blanco19, L Gottesman12, CH Feldman2, R Ramsey-Goldman20 1 Analysis Institute on the McGill University Health Centre, Montreal, QC, Canada; 2Brigham and Women's Hospital, Harvard Medical College, Boston, MA, USA; 3Toronto Western Hospital and University of Toronto, Toronto, ON, Canada; 4University of Laval, QC, Canada; 5Johns Hopkins University College of Medicine, Baltimore, MD, USA; 6West Penn Allegheny Well being Method,Arthritis Research Therapy 2012, Volume 14 Suppl three http://arthritis-research.com/supplements/14/SPage 7 ofPittsburgh, PA, USA; 7University College of London, UK; 8Cedars-Sinai/UCLA, Los Angeles, CA, USA; 9University of Birmingham, UK; 10University of Manitoba, Winnipeg, MB, Canada; 11University of North Carolina at Chapel Hill, NC, USA; 12SUNY - Downstate Health-related Center, Brooklyn, NY, USA; 13 title= rstb.2014.0252 Feinstein Institute for Health-related Analysis, Manhasset, NY, USA; 14The University of Calgary, AB, Canada; 15University Hospital - Lund, Sweden; 16 Copenhagen University Hospital, Copenhagen, Denmark; 17Hospital de Cruces, UPV/EHU, Barakaldo, Spain; 18University of California San Francisco, CA, USA; 19Albert Einstein College of Medicine, Bronx, NY, USA; 20 Northwestern University Feinberg College of Medicine, Chicago, IL, USA Arthritis Analysis Therapy 2012, 14(Suppl three):ABackground: We not too long ago evaluated the risk of malignancy in SLE by linking a multi-site international SLE cohort with regional tumor registries. Across 28 centers, 15,980 individuals had been observed for 119,846 (typical 7.five) personyears. In total, 641 cancers occurred, for an all round standardized incidence ratio (SIR) of 1.14 (95 CI = 1.06 to 1.24). Hematologic malignancies had been substantially increased (SIR = three.01, 95 CI = 2.47 to 3.62), specifically nonHodgkin's lymphoma (NHL; SIR = four.36, 95 CI title= bmjopen-2014-007528 = 3.43 to five.47) and leukemia (SIR = 1.76, 95 CI = 1.04 to two.78) [1]. But the relative influence of treatment versus illness activity is unknown. Our objective was to ascertain the relative significance of drugs versus illness activity in mediating the increased risk of lymphoma. Strategies: We performed case-cohort analyses within this multi-site SLE cohort. Adjusted hazard ratios (HRs) for lymphoma had been generated in multivariate regression models, for time-dependent exposures to immunomodulators (cyclophosphamide, azathioprine, methotrexate, mycophenolate, antimalarials, glucocorticoids), illness activity (mean adjusted SLEDAI-2K), demographics, calendar year, Sj ren's syndrome, and SLE duration. Partially adjusted models have been also performed, using only covariates whose HR CI excluded the null. Sensitivity analyses have been performed, lagging cyclophosphamide exposures by five years. Medicines have been treated each categorically (ever/never) and as cumulative doses.